Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors
Open Access
- 7 April 2022
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 9 (1) , e001931
Abstract
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an important but underutilised option to help optimise lipid management. We developed a new service to improve patient access to these medicines in line with National Institute for Health and Care Excellence recommendations. This paper describes the model and provides lipid-lowering results and feedback from the first 100 referred patients. Methods: The service is based on a centralised multidisciplinary clinic that is the sole prescriber of PCSK9i therapy in the area. Referred patients are assessed for eligibility and given tailored, person-centred support, education and monitoring to promote treatment adherence and lipids optimisation. The clinic also supports referred patients that do not meet PCSK9i eligibility criteria. Results: Among the first 100 patients referred (n=62 male; mean age: 62.9±10.5 years), 48 were initiated on PCSK9i therapy. Mean total cholesterol decreased from 7.7±1.6 mmol/L at baseline to 4.5±1.4 mmol/L at 3 months (41% reduction), while mean low-density lipoprotein-cholesterol (LDL-C) fell from 5.0±1.6 mmol/L to 2.1±1.3 mmol/L (58% reduction; p<0.0001 for the decrease in mean LDL-C from baseline). Patient feedback on the clinic was positive and overall satisfaction was high. Conclusions: This innovative, person-centred, multidisciplinary service successfully initiated PCSK9i therapy for eligible patients and drove long-term monitoring, adherence and cholesterol lowering. It also provided medicines optimisation and adherence assistance to PCSK9i-ineligible patients. The model could be used in other areas to support better uptake and optimisation of PCSK9i therapy.Keywords
This publication has 24 references indexed in Scilit:
- Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation ServiceJournal of Managed Care & Specialty Pharmacy, 2017
- PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews, 2017
- Comprehensive efforts to increase adherence to statin therapyEuropean Heart Journal, 2017
- Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementInternational Journal of Cardiology, 2016
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016
- PS1-45: Prevalence of Statin Intolerance in a High Risk Cohort and Management Strategies in Contemporary CardiologyClinical Medicine & Research, 2013
- Discontinuation of Statins in Routine Care SettingsAnnals of Internal Medicine, 2013
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences, 2009
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.BMJ, 1991